Merus Labs International Inc. (TSE:MSL – Free Report) (NASDAQ:MSLI) – Equities researchers at HC Wainwright issued their FY2029 earnings per share estimates for shares of Merus Labs International in a research note issued to investors on Thursday, March 27th. HC Wainwright analyst A. He expects that the specialty pharmaceutical company will post earnings of ($0.13) per share for the year.
Merus Labs International Stock Performance
The firm’s fifty day moving average price is C$1.65. Merus Labs International has a 52 week low of C$0.95 and a 52 week high of C$1.76.
About Merus Labs International
Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin.
Read More
- Five stocks we like better than Merus Labs International
- What is Forex and How Does it Work?
- Ibotta Stock: Why the Buyback Looks Like a Bullish Bet
- How to Invest in Insurance Companies: A Guide
- Joby Aviation Stock: Analyst Confidence and Smart Money Align
- What Are Treasury Bonds?
- 3 Momentum Stocks Near 52-Week Highs to Watch for More Growth
Receive News & Ratings for Merus Labs International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International and related companies with MarketBeat.com's FREE daily email newsletter.
